ANI Pharmaceuticals, Inc. $ANIP Shares Bought by Sei Investments Co.

Sei Investments Co. grew its stake in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) by 36.8% during the 1st quarter, Holdings Channel reports. The fund owned 57,168 shares of the specialty pharmaceutical company’s stock after acquiring an additional 15,367 shares during the period. Sei Investments Co.’s holdings in ANI Pharmaceuticals were worth $4,395,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Maryland State Retirement & Pension System lifted its holdings in ANI Pharmaceuticals by 5.4% in the 4th quarter. Maryland State Retirement & Pension System now owns 2,613 shares of the specialty pharmaceutical company’s stock valued at $206,000 after purchasing an additional 134 shares in the last quarter. CANADA LIFE ASSURANCE Co boosted its stake in shares of ANI Pharmaceuticals by 1.0% during the 2nd quarter. CANADA LIFE ASSURANCE Co now owns 19,408 shares of the specialty pharmaceutical company’s stock worth $1,267,000 after purchasing an additional 198 shares during the last quarter. Oregon Public Employees Retirement Fund grew its holdings in shares of ANI Pharmaceuticals by 5.1% during the fourth quarter. Oregon Public Employees Retirement Fund now owns 4,086 shares of the specialty pharmaceutical company’s stock worth $323,000 after buying an additional 200 shares in the last quarter. Federation des caisses Desjardins du Quebec grew its holdings in shares of ANI Pharmaceuticals by 0.6% during the fourth quarter. Federation des caisses Desjardins du Quebec now owns 39,391 shares of the specialty pharmaceutical company’s stock worth $3,110,000 after buying an additional 221 shares in the last quarter. Finally, Hantz Financial Services Inc. raised its position in shares of ANI Pharmaceuticals by 70.3% in the fourth quarter. Hantz Financial Services Inc. now owns 603 shares of the specialty pharmaceutical company’s stock valued at $48,000 after buying an additional 249 shares during the last quarter. Hedge funds and other institutional investors own 76.05% of the company’s stock.

Analyst Ratings Changes

A number of brokerages recently issued reports on ANIP. Canaccord Genuity Group began coverage on shares of ANI Pharmaceuticals in a research report on Thursday, July 16th. They set a “hold” rating and a $91.00 target price on the stock. Zacks Research lowered ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Thursday, May 14th. Guggenheim restated a “buy” rating and set a $124.00 price objective on shares of ANI Pharmaceuticals in a report on Friday, July 10th. Wall Street Zen raised ANI Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Saturday, May 9th. Finally, Weiss Ratings raised ANI Pharmaceuticals from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Tuesday, June 23rd. Six analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat, ANI Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus target price of $105.00.

Insiders Place Their Bets

In other ANI Pharmaceuticals news, SVP Ori Gutwerg sold 2,772 shares of the company’s stock in a transaction dated Tuesday, May 12th. The stock was sold at an average price of $79.50, for a total transaction of $220,374.00. Following the completion of the sale, the senior vice president directly owned 78,696 shares in the company, valued at $6,256,332. This represents a 3.40% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Patrick D. Walsh sold 10,000 shares of the firm’s stock in a transaction dated Wednesday, May 13th. The stock was sold at an average price of $80.63, for a total value of $806,300.00. Following the completion of the transaction, the director owned 38,432 shares in the company, valued at approximately $3,098,772.16. This trade represents a 20.65% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 88,029 shares of company stock worth $6,954,472. Corporate insiders own 8.10% of the company’s stock.

ANI Pharmaceuticals Price Performance

ANI Pharmaceuticals stock opened at $79.88 on Thursday. ANI Pharmaceuticals, Inc. has a 1 year low of $64.99 and a 1 year high of $99.50. The firm has a 50 day moving average price of $80.99 and a 200 day moving average price of $79.39. The company has a market cap of $1.82 billion, a price-to-earnings ratio of 20.22 and a beta of 0.44. The company has a debt-to-equity ratio of 1.06, a quick ratio of 2.52 and a current ratio of 3.12.

ANI Pharmaceuticals (NASDAQ:ANIP) last posted its quarterly earnings results on Friday, May 8th. The specialty pharmaceutical company reported $2.05 earnings per share for the quarter, topping analysts’ consensus estimates of $1.28 by $0.77. The company had revenue of $237.46 million for the quarter, compared to the consensus estimate of $207.63 million. ANI Pharmaceuticals had a net margin of 9.98% and a return on equity of 27.51%. ANI Pharmaceuticals’s revenue was up 20.5% on a year-over-year basis. During the same quarter last year, the firm posted $1.70 earnings per share. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. Sell-side analysts predict that ANI Pharmaceuticals, Inc. will post 8.03 earnings per share for the current year.

ANI Pharmaceuticals Profile

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.